|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000170837 |
Summary for GPR27 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000170837 | Gene symbol | GPR27 |
| Gene name | G protein-coupled receptor 27 | |
| HGNC | 4482 | |
| Entrez ID | 2850 | |
| Gene type | protein_coding | |
| Synonyms | GPR27|SREB1 | |
| UniProtAcc | Q9NS67 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for GPR27 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| GPR27 | 2.34e+02 | -1.35e+00 | 2.90e-01 | -4.67e+00 | 2.98e-06 | 5.06e-05 | KIRP |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| GPR27 | 1.83e+02 | -1.19e+00 | 4.89e-01 | -2.43e+00 | 1.53e-02 | 2.57e-02 | KIRP |
| GPR27 | 1.94e+02 | -1.48e+00 | 6.46e-01 | -2.28e+00 | 2.24e-02 | 4.10e-02 | KICH |
| GPR27 | 1.65e+02 | 3.80e+00 | 7.19e-01 | 5.29e+00 | 1.26e-07 | 1.11e-06 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Top |
Sex-biased somatic mutation for GPR27 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for GPR27 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LIHC | cg03457142 | chr3:71755708 | CGI:chr3:71753409-71755058 | UTR,promoter,exon,gene body | 4.99e-01 | 3.81e-01 | 4.32e+00 | 1.54e-05 | 1.57e-04 | 1.19e-01 |
| KIRP | cg13026730 | chr3:71754988 | CGI:chr3:71753409-71755058 | promoter,exon,CDS,gene body | 4.70e-01 | 3.46e-01 | 4.08e+00 | 4.42e-05 | 3.76e-04 | 1.24e-01 |
| KIRP | cg04087740 | chr3:71754991 | CGI:chr3:71753409-71755058 | promoter,exon,CDS,gene body | 4.82e-01 | 3.50e-01 | 4.27e+00 | 1.93e-05 | 1.77e-04 | 1.32e-01 |
| SARC | cg13026730 | chr3:71754988 | CGI:chr3:71753409-71755058 | promoter,exon,CDS,gene body | 5.20e-01 | 4.20e-01 | 3.03e+00 | 2.48e-03 | 6.93e-03 | 1.00e-01 |
| SARC | cg04087740 | chr3:71754991 | CGI:chr3:71753409-71755058 | promoter,exon,CDS,gene body | 5.56e-01 | 4.33e-01 | 3.60e+00 | 3.23e-04 | 1.40e-03 | 1.23e-01 |
| GBM | cg22823146 | chr3:71753443 | CGI:chr3:71753409-71755058 | promoter | 2.74e-01 | 3.81e-01 | -2.06e+00 | 3.98e-02 | 4.60e-02 | -1.07e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| THCA | cg04087740 | chr3:71754991 | CGI:chr3:71753409-71755058 | promoter,exon,CDS,gene body | 4.59e-01 | 3.54e-01 | 2.16e+00 | 3.09e-02 | 3.63e-02 | 1.06e-01 |
| HNSC | cg13026730 | chr3:71754988 | CGI:chr3:71753409-71755058 | promoter,exon,CDS,gene body | 4.55e-01 | 3.23e-01 | 3.01e+00 | 2.57e-03 | 4.04e-03 | 1.32e-01 |
| HNSC | cg04087740 | chr3:71754991 | CGI:chr3:71753409-71755058 | promoter,exon,CDS,gene body | 4.48e-01 | 3.09e-01 | 3.13e+00 | 1.77e-03 | 2.94e-03 | 1.39e-01 |
| LUSC | cg13026730 | chr3:71754988 | CGI:chr3:71753409-71755058 | promoter,exon,CDS,gene body | 4.86e-01 | 2.92e-01 | 2.60e+00 | 9.45e-03 | 1.33e-02 | 1.94e-01 |
| LUSC | cg04087740 | chr3:71754991 | CGI:chr3:71753409-71755058 | promoter,exon,CDS,gene body | 4.86e-01 | 2.99e-01 | 2.60e+00 | 9.19e-03 | 1.30e-02 | 1.87e-01 |
| BLCA | cg03457142 | chr3:71755708 | CGI:chr3:71753409-71755058 | UTR,promoter,exon,gene body | 6.03e-01 | 7.44e-01 | -2.89e+00 | 3.82e-03 | 6.57e-03 | -1.42e-01 |
| LIHC | cg13562542 | chr3:71754188 | CGI:chr3:71753409-71755058 | promoter,exon,CDS,gene body | 3.52e-01 | 7.41e-02 | 2.91e+00 | 3.61e-03 | 4.95e-03 | 2.78e-01 |
| LIHC | cg10172415 | chr3:71754407 | CGI:chr3:71753409-71755058 | promoter,exon,CDS,gene body | 2.30e-01 | 2.82e-02 | 3.10e+00 | 1.95e-03 | 2.86e-03 | 2.02e-01 |
| LIHC | cg03457142 | chr3:71755708 | CGI:chr3:71753409-71755058 | UTR,promoter,exon,gene body | 3.81e-01 | 5.58e-01 | -4.68e+00 | 2.86e-06 | 9.19e-06 | -1.78e-01 |
| CHOL | cg13026730 | chr3:71754988 | CGI:chr3:71753409-71755058 | promoter,exon,CDS,gene body | 4.49e-01 | 1.56e-01 | 2.80e+00 | 5.09e-03 | 1.63e-02 | 2.94e-01 |
| CHOL | cg04087740 | chr3:71754991 | CGI:chr3:71753409-71755058 | promoter,exon,CDS,gene body | 4.75e-01 | 1.77e-01 | 2.73e+00 | 6.38e-03 | 1.82e-02 | 2.99e-01 |
| CHOL | cg03457142 | chr3:71755708 | CGI:chr3:71753409-71755058 | UTR,promoter,exon,gene body | 7.10e-01 | 5.01e-01 | 3.24e+00 | 1.18e-03 | 1.07e-02 | 2.09e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg13026730 | chr3:71754988 | CGI:chr3:71753409-71755058 | promoter,exon,CDS,gene body | 3.90e-01 | 2.37e-01 | 6.46e+00 | 1.03e-10 | 2.70e-10 | 1.53e-01 |
| BRCA | cg04087740 | chr3:71754991 | CGI:chr3:71753409-71755058 | promoter,exon,CDS,gene body | 3.93e-01 | 2.15e-01 | 7.13e+00 | 1.01e-12 | 3.10e-12 | 1.78e-01 |
| BRCA | cg22631938 | chr3:71753269 | CGI:chr3:71753409-71755058 | promoter | 5.49e-01 | 4.27e-01 | 6.05e+00 | 1.47e-09 | 3.52e-09 | 1.22e-01 |
| HNSC | cg10172415 | chr3:71754407 | CGI:chr3:71753409-71755058 | promoter,exon,CDS,gene body | 1.35e-01 | 1.65e-02 | 3.18e+00 | 1.48e-03 | 9.25e-03 | 1.18e-01 |
| KIRP | cg04087740 | chr3:71754991 | CGI:chr3:71753409-71755058 | promoter,exon,CDS,gene body | 4.82e-01 | 3.03e-01 | 2.17e+00 | 3.01e-02 | 3.53e-02 | 1.79e-01 |
Top |
Exon skipping events with PSI in TCGA for GPR27 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for GPR27 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for GPR27 |
| TFs related to GPR27. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| GPR27 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for GPR27 |
| RBPs related to ES in GPR27. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| GPR27 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
| ENSG00000170837 | AL445309.1,hsa-mir-497,GPR27 | Male-specific ceRNA | TCGA-KIRP |
| ENSG00000170837 | TEX41,hsa-mir-497,GPR27 | Male-specific ceRNA | TCGA-KIRP |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs9865881 | chr3:68038355:T:C | - | 0.366672876821265 | 0.0181353913811212 | GBM | Female-baised eQTL |
| rs9866037 | chr3:68038462:T:G | - | 0.366672876821265 | 0.0181353913811212 | GBM | Female-baised eQTL |
| rs9853286 | chr3:68040406:C:T | - | 0.366672876821265 | 0.0181353913811212 | GBM | Female-baised eQTL |
| rs9814521 | chr3:68040418:G:A | - | 0.366672876821265 | 0.0181353913811212 | GBM | Female-baised eQTL |
| rs13327832 | chr3:68042659:A:C | - | 0.366672876821265 | 0.0181353913811212 | GBM | Female-baised eQTL |
| rs13324214 | chr3:68042661:C:A | - | 0.366672876821265 | 0.0181353913811212 | GBM | Female-baised eQTL |
| rs11926885 | chr3:68043951:C:T | - | 0.366672876821265 | 0.0181353913811212 | GBM | Female-baised eQTL |
| rs62246081 | chr3:73466668:G:A | - | 0.214594596987983 | 0.0265055425593884 | GBM | Female-baised eQTL |
| rs55764535 | chr3:73469014:A:G | - | 0.214594596987983 | 0.0265055425593884 | GBM | Female-baised eQTL |
| rs56799456 | chr3:73469375:T:C | - | 0.214594596987983 | 0.0265055425593884 | GBM | Female-baised eQTL |
| rs1038386 | chr3:69376000:G:A | - | -0.141229987907529 | 0.0414671206463042 | KIRC | Female-baised eQTL |
| rs1038385 | chr3:69376012:A:G | - | -0.141093675825926 | 0.042123187105228 | KIRC | Female-baised eQTL |
| rs13317977 | chr3:74151068:T:C | - | 0.167605802147563 | 0.000328896227464876 | BLCA | Female-baised eQTL |
| rs57803044 | chr3:74166058:T:C | - | 0.167605802147563 | 0.000328896227464876 | BLCA | Female-baised eQTL |
| rs1562482 | chr3:74137027:C:T | - | 0.159361367857829 | 0.000681243477545899 | BLCA | Female-baised eQTL |
| rs6799162 | chr3:74164422:C:T | - | 0.147253322728813 | 0.00245778808135037 | BLCA | Female-baised eQTL |
| rs60007047 | chr3:74165880:T:C | - | 0.147253322728813 | 0.00245778808135037 | BLCA | Female-baised eQTL |
| rs58718946 | chr3:74165894:A:C | - | 0.147253322728813 | 0.00245778808135037 | BLCA | Female-baised eQTL |
| rs73107839 | chr3:70478181:G:T | - | 0.153805860220656 | 0.00288906768824719 | BLCA | Female-baised eQTL |
| rs61340957 | chr3:74165968:T:G | - | 0.148971008741801 | 0.00320022282927614 | BLCA | Female-baised eQTL |
| rs13434030 | chr3:74151798:G:A | - | 0.139115909509555 | 0.00497356856296532 | BLCA | Female-baised eQTL |
| rs7647829 | chr3:70117075:G:A | - | 0.16590525813406 | 0.00721034969481123 | BLCA | Female-baised eQTL |
| rs73113361 | chr3:74201665:T:C | - | 0.12562659088798 | 0.0113721411478057 | BLCA | Female-baised eQTL |
| rs73114532 | chr3:74178266:T:A | - | 0.125302998972231 | 0.0118866551565082 | BLCA | Female-baised eQTL |
| rs73114540 | chr3:74186983:T:G | - | 0.125302998972231 | 0.0118866551565082 | BLCA | Female-baised eQTL |
| rs73113351 | chr3:74198448:T:C | - | 0.12518635819267 | 0.0121884364939621 | BLCA | Female-baised eQTL |
| rs76350149 | chr3:73568087:T:C | - | 0.109108458295434 | 0.0144502450646278 | BLCA | Female-baised eQTL |
| rs66566537 | chr3:74155367:C:T | - | 0.121690134137763 | 0.0185326994648958 | BLCA | Female-baised eQTL |
| rs67335601 | chr3:74155441:G:A | - | 0.121690134137763 | 0.0185326994648958 | BLCA | Female-baised eQTL |
| rs144403814 | chr3:74161636:C:T | - | 0.121690134137763 | 0.0185326994648958 | BLCA | Female-baised eQTL |
| rs17012190 | chr3:74207334:C:T | - | 0.132500574603376 | 0.0189836548748369 | BLCA | Female-baised eQTL |
| rs8180009 | chr3:70233981:T:C | - | 0.151313688956958 | 0.0303669001719204 | BLCA | Female-baised eQTL |
| rs1125009 | chr3:70238336:C:T | - | 0.151313688956958 | 0.0303669001719204 | BLCA | Female-baised eQTL |
| rs73113366 | chr3:74204612:T:C | - | 0.117920726795634 | 0.0376479786682175 | BLCA | Female-baised eQTL |
| rs1466074 | chr3:74172791:T:G | - | 0.0990228723020605 | 0.0421216262144997 | BLCA | Female-baised eQTL |
| rs7644555 | chr3:70473065:A:G | - | 0.121627027107617 | 0.0426332981185356 | BLCA | Female-baised eQTL |
| rs113380723 | chr3:70479041:A:G | - | 0.121627027107617 | 0.0426332981185356 | BLCA | Female-baised eQTL |
| rs11128347 | chr3:73570410:G:C | - | 0.0984829644153513 | 0.0428430998814527 | BLCA | Female-baised eQTL |
| rs146998311 | chr3:76398003:C:G | - | 0.146364564970641 | 0.0455222019202515 | BLCA | Female-baised eQTL |
| rs72631204 | chr3:76390996:A:G | - | 0.146368314379121 | 0.0457553461055609 | BLCA | Female-baised eQTL |
| rs28465323 | chr3:73316909:A:G | - | 0.0892497327458426 | 0.0381698065932716 | LUAD | Female-baised eQTL |
| rs35934900 | chr3:73317214:A:C | - | 0.0887534234507422 | 0.040518545763608 | LUAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs7428284 | chr3:77169857:G:T | - | 0.147844667001978 | 0.00248628559662562 | LUAD | Male-baised eQTL |
| rs77652315 | chr3:77171805:G:A | - | 0.147844667001978 | 0.00248628559662562 | LUAD | Male-baised eQTL |
| rs79081107 | chr3:77179135:T:A | - | 0.147844667001978 | 0.00248628559662562 | LUAD | Male-baised eQTL |
| rs1551203 | chr3:62624849:C:T | - | 0.0839654452191615 | 0.00275611611905246 | LUAD | Male-baised eQTL |
| rs7427254 | chr3:77183535:T:G | - | 0.144992475497592 | 0.00308182788260356 | LUAD | Male-baised eQTL |
| rs7624666 | chr3:77183698:A:T | - | 0.144992475497592 | 0.00308182788260356 | LUAD | Male-baised eQTL |
| rs78117692 | chr3:77184414:A:G | - | 0.144992475497592 | 0.00308182788260356 | LUAD | Male-baised eQTL |
| rs116800061 | chr3:62646226:G:A | - | 0.131893720852621 | 0.00347060257135145 | LUAD | Male-baised eQTL |
| rs1398095 | chr3:62624382:C:T | - | 0.0793612894600354 | 0.00484020332173342 | LUAD | Male-baised eQTL |
| rs144917658 | chr3:62649538:G:A | - | 0.12749667931929 | 0.00566199224911934 | LUAD | Male-baised eQTL |
| rs2578349 | chr3:81032338:T:C | - | -0.0847779624929087 | 0.0213072461343886 | LUAD | Male-baised eQTL |
| rs62251064 | chr3:77455638:G:A | - | 0.105572402735776 | 0.0217288552657631 | LUAD | Male-baised eQTL |
| rs62253902 | chr3:65016958:A:G | - | 0.09866142641211 | 0.0234842692079185 | LUAD | Male-baised eQTL |
| rs62253903 | chr3:65018070:G:A | - | 0.09866142641211 | 0.0234842692079185 | LUAD | Male-baised eQTL |
| rs17476108 | chr3:81551923:G:A | - | 0.0962673864231347 | 0.0236326771068544 | LUAD | Male-baised eQTL |
| rs2004224 | chr3:62820819:C:T | - | -0.161365787990618 | 0.0245293187456833 | LUAD | Male-baised eQTL |
| rs56082019 | chr3:73619734:G:A | - | 0.122502996719703 | 0.0257811667702874 | LUAD | Male-baised eQTL |
| rs74415865 | chr3:79255692:G:A | - | 0.146168443322607 | 0.0300500376240544 | LUAD | Male-baised eQTL |
| rs80052011 | chr3:79249509:T:A | - | 0.145953737210881 | 0.0304908791641541 | LUAD | Male-baised eQTL |
| rs78783762 | chr3:77139424:T:A | - | 0.123991299130244 | 0.0331672355918852 | LUAD | Male-baised eQTL |
| rs10510880 | chr3:62634456:T:C | - | 0.0664109924123829 | 0.0372853979135158 | LUAD | Male-baised eQTL |
| rs13084034 | chr3:62634698:A:G | - | 0.066419810538368 | 0.0381356255221673 | LUAD | Male-baised eQTL |
| rs186235 | chr3:62798753:C:T | - | -0.14653763180524 | 0.0397454587153598 | LUAD | Male-baised eQTL |
| rs77699281 | chr3:79246350:C:T | - | 0.105853522227502 | 0.0422977922244137 | LUAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000170837 |
| CpG Site: cg20863339 | |
| Position to Gene: gene,exon,CDS,promoter | |
| Male Effect: - | |
| Female Effect: -0.42081218728224 | |
 | Gene ID: ENSG00000170837 |
| CpG Site: cg20863339 | |
| Position to Gene: gene,exon,CDS,promoter | |
| Male Effect: - | |
| Female Effect: -0.291291539153694 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg20863339 | chr3:71754854 | gene,exon,CDS,promoter | -0.42081218728224 | 4.41970543531413e-07 | -0.6279711546825189 | 4.521582761683793e-10 | PAAD |
| cg20863339 | chr3:71754854 | gene,exon,CDS,promoter | -0.291291539153694 | 3.09237831839344e-06 | -0.3506146237647494 | 8.659845730691549e-09 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of GPR27 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000170837 | GPR27 | C0345967 | Malignant mesothelioma | 1 | CTD_human |
